Prevalence of Drug Resistance in Chronic Hepatitis C Patients
Author Information
Author(s): Inzaule Seth, Easterbrook Philippa, Latona Ashley, Ford Nathan P, Irving William, Matthews Philippa C, Vitoria Marco, Duncombe Chris, Giron Amalia, McCluskey Suzanne, Lesi Olufunmilayo, Tchamgoue Serge, Halford Rachel, Adda Danjuma, Thomson Emma, Dusheiko Geoff, Jordan Michael R
Primary Institution: Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam
Hypothesis
What is the prevalence of drug resistance associated substitutions in chronic hepatitis C patients who experience virological failure after treatment with direct-acting antivirals?
Conclusion
The study found a high prevalence of drug resistance mutations in chronic hepatitis C patients who failed treatment with direct-acting antivirals.
Supporting Evidence
- The pooled prevalence of resistance-associated substitutions was found to be 79.0% overall.
- Resistance to NS5A inhibitors was particularly high among patients with virological failure.
- Patients with virological failure after re-treatment had an even higher prevalence of resistance mutations.
Takeaway
Many people with chronic hepatitis C who don't get better after treatment have mutations that make the virus resistant to the medicine.
Methodology
A systematic review and meta-analysis of studies assessing drug resistance mutations in chronic hepatitis C patients.
Potential Biases
Potential bias due to exclusion of non-English studies and limited data from certain regions.
Limitations
The review only included studies published in English and may not represent regional variations in drug resistance.
Participant Demographics
The studies included patients with chronic hepatitis C from various regions, primarily from the WHO European Region.
Statistical Information
Confidence Interval
95% CI: 70.0–87.0
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website